The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis
Open accessAbstract
Background— There is uncertainty about the association between circulating concentrations of adiponectin and coronary heart disease (CHD) risk. We report new data from a prospective study in the context of a meta-analysis of previously published prospective studies. Methods and Results— We measured baseline adiponectin levels in stored serum samples of 589 men with fatal CHD or nonfatal myocardial infarction and in 1231 controls nested within a prospective study of 5661 men (aged 40 to 59 years) recruited during 1978–1980, as well as in paired samples obtained 4 years apart from 221 of these participants. Baseline adiponectin concentrations correlated ( P <0.0001) positively with HDL cholesterol ( r =0.33) and inversely with C-reactive protein ( r =−0.11) and BMI ( r =−0.21), and the year-to-year consistency of adiponectin values was comparable to those of blood pressure and total cholesterol levels. No significant difference between median adiponectin levels at baseline was observed between cases and controls (10.2 versus 10.8 μg/mL; P =0.5), despite the fact that body mass index, HDL, and C-reactive protein were all significant predictors of events in this cohort. The odds ratio for CHD was 0.89 (95% CI, 0.67 to 1.18) in a comparison of men in the top third of adiponectin concentrations compared with those in the bottom third, similar to a meta-analysis (including the present study) of 7 prospective studies involving a total of 1318 CHD cases (odds ratio, 0.84 [95% CI, 0.70 to 1.01]). Conclusions— In contrast to the strong associations previously reported between adiponectin levels and risk of type 2 diabetes, any association with CHD risk is comparatively moderate and requires further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A. M., & Pajak, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,263
Novel Modulator for Endothelial Adhesion Molecules: Adipocyte-Derived Plasma Protein Adiponectin
Ouchi, N., Kihara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., Hotta, K., Nishida, M., Takahashi, M., Nakamura, T., et al. (1999) · Circulation · doi:10.1161/01.cir.100.25.2473 · Cited by 2,147
Danesh, J., Collins, R., Appleby, P., & Peto, R. (1998) · JAMA · doi:10.1001/jama.279.18.1477 · Cited by 2,026
Self-citationPlasma Adiponectin Levels and Risk of Myocardial Infarction in Men
Pischon, T. (2004) · JAMA · doi:10.1001/jama.291.14.1730 · Cited by 1,773
Ouchi, N., Kihara, S., Arita, Y., Okamoto, Y., Maeda, K., Kuriyama, H., Hotta, K., Nishida, M., Takahashi, M., Muraguchi, M., et al. (2000) · Circulation · doi:10.1161/01.cir.102.11.1296 · Cited by 1,737
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Self-citationEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Adiponectin and protection against type 2 diabetes mellitus
Spranger, J., Kroke, A., Möhlig, M., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12255-6 · Cited by 1,120
Adiponectin and development of type 2 diabetes in the Pima Indian population
Lindsay, R. S., Funahashi, T., Hanson, R. L., Matsuzawa, Y., Tanaka, S., Tataranni, P. A., Knowler, W. C., & Krakoff, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09335-2 · Cited by 1,094
Cited by
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“Although adiponectin has numerous effects on the arterial wall, on the liver, as well as on insulin actions, its independent contribution to the etiology of CVD remains controversial as a systematic review and meta-analysis failed to identify this adipokine as an independent risk factor for cardiovascular outcomes (49…”
BackgroundAdipose tissue dysfunction in obesity, diabetes, and vascular diseases
Hajer, G. R., van Haeften, T. W., & Visseren, F. L. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn387 · Cited by 1,410
Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction
Achari, A., & Jain, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061321 · Cited by 1,158
Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome
Maury, E., & Brichard, S. M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.07.031 · Cited by 1,026
Adiponectin as an anti-inflammatory factor
Ouchi, N., & Walsh, K. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.01.026 · Cited by 872
Abel, E. D., Litwin, S. E., & Sweeney, G. (2008) · Physiological Reviews · doi:10.1152/physrev.00017.2007 · Cited by 736
“Nevertheless, some studies reported little correlation with adiponectin and risk factors for CHD, whereas adiponectin was clearly inversely associated with diabetic risk factors in all studies (309, 372), leading some to suggest that adiponectin’s influence on CHD may principally occur secondary to diabetes.”
ResultScheen, A. J., Finer, N., Hollander, P., Jensen, M. D., & Van Gaal, L. F. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 736
Davidovici, B. B., Sattar, N., Jörg, P. C., Puig, L., Emery, P., Barker, J. N., van de Kerkhof, P., Ståhle, M., Nestle, F. O., Girolomoni, G., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.103 · Cited by 711
Self-citationFuster, J. J., Ouchi, N., Gokce, N., & Walsh, K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306885 · Cited by 664
Adiponectin regulation and function
Fang, H., & Judd, R. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170046 · Cited by 631
Adipokines: A link between obesity and cardiovascular disease
Nakamura, K., Fuster, J. J., & Walsh, K. (2014) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.11.006 · Cited by 578
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
Obesity and the risk of cardiometabolic diseases
Valenzuela, P. L., Carrera-Bastos, P., Castillo-García, A., Lieberman, D. E., Santos-Lozano, A., & Lucia, A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00847-5 · Cited by 452
Inflammation, a Link between Obesity and Cardiovascular Disease
Wang, Z., & Nakayama, T. (2010) · Mediators of Inflammation · doi:10.1155/2010/535918 · Cited by 412
Inflammation Impairs Reverse Cholesterol Transport In Vivo
McGillicuddy, F. C., de la Llera Moya, M., Hinkle, C. C., Joshi, M. R., Chiquoine, E. H., Billheimer, J. T., Rothblat, G. H., & Reilly, M. P. (2009) · Circulation · doi:10.1161/circulationaha.108.810721 · Cited by 391
Adiponectin actions in the cardiovascular system
HOPKINS, T., OUCHI, N., SHIBATA, R., & WALSH, K. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.009 · Cited by 327
Adiponectin action from head to toe
Brochu-Gaudreau, K., Rehfeldt, C., Blouin, R., Bordignon, V., Murphy, B. D., & Palin, M.-F. (2010) · Endocrine · doi:10.1007/s12020-009-9278-8 · Cited by 322
Lara-Castro, C., Fu, Y., Chung, B. H., & Garvey, W. T. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32814a645f · Cited by 315
Blood Markers for the Prognosis of Ischemic Stroke: A Systematic Review
Whiteley, W., Chong, W. L., Sengupta, A., & Sandercock, P. (2009) · Stroke · doi:10.1161/strokeaha.108.528752 · Cited by 290
Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease
Menzaghi, C., Trischitta, V., & Doria, A. (2007) · Diabetes · doi:10.2337/db06-0506 · Cited by 276
Ioannidis, J. P. A. (2011) · JAMA · doi:10.1001/jama.2011.713 · Cited by 252
Adiponectin, driver or passenger on the road to insulin sensitivity?
Ye, R., & Scherer, P. E. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.04.001 · Cited by 251
Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function
Stadler, J. T., & Marsche, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238985 · Cited by 200
Gender aspects in type 2 diabetes mellitus and cardiometabolic risk
Sattar, N. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.006 · Cited by 177
Self-citationInflammation, adiponectin, obesity and cardiovascular risk
Mangge, H., Almer, G., Truschnig-Wilders, M., Schmidt, A., Gasser, R., & Fuchs, D. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710794183006 · Cited by 142
Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?
Sattar, N., Wannamethee, S. G., & Forouhi, N. G. (2008) · Diabetologia · doi:10.1007/s00125-008-0954-7 · Cited by 143
Self-citationFargnoli, J. L., Fung, T. T., Olenczuk, D. M., Chamberland, J. P., Hu, F. B., & Mantzoros, C. S. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26480 · Cited by 124
Wu, J. H. Y., Cahill, L. E., & Mozaffarian, D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3899 · Cited by 83
Hao, G., Li, W., Guo, R., Yang, J.-G., Wang, Y., Tian, Y., Liu, M.-Y., Peng, Y.-G., & Wang, Z.-W. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.018 · Cited by 82
Menzaghi, C., Xu, M., Salvemini, L., De Bonis, C., Palladino, G., Huang, T., Copetti, M., Zheng, Y., Li, Y., Fini, G., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0130-y · Cited by 40
Metadata
- Authors
- Sattar, N., Wannamethee, G., Sarwar, N., Tchernova, J., Cherry, L., Wallace, A. M., Danesh, J., & Whincup, P. H.
- Venue
- Circulation
- Published
- 2006-08-15
- Volume
- 114
- Issue
- 7
- Pages
- 623-629
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2003224969
- Cited by
- 403
- References
- 35
- FWCI
- 23.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.